



DAVID ALIPOUR
CEO
AI Med Global



STEPHANIE ALLEN
Director of Innovation Services
California Life Sciences



JULIE AMES
Vice President
Biocom California



KATE BRODERICK
Senior Vice President,
Research & Development
TriLink BioTechnologies



MASSIMO CALAFIORE
Executive Vice President and
Chief Commercial Officer
NuVasive



ALLAN CAMAISA
Chairman and CEO
Calidi Biotherapeutics



ENRIQUE CENICERROS
Director of Science +
Technology
Taylor Design



JAIME D. CHOI
Partner, Co-Chair of Life
Sciences and Medical
Technology Industry Group
Snell & Wilmer



**JEAN-CLAUDE
CONSTANDE**
Principal
CPCArchitects



**JAMI DEBRANGO-
PALUMBO**
Senior Vice President, Client
Services and Operations
Foundation Medicine



**STEPHANIE
CULLER**
Co-founder and CEO
Persephone Biosciences



PETER DOWLEY
Senior Vice President,
Investments, San Diego &
Life Science
Kilroy



ARTHUR DEPTALA
CEO
Pathway NPI



TOM GILMAN
President and CEO
Biosero, Inc.



TOM GIUGGIO
Vice President and Senior
Lab Planner
HKS Architects



SMITA GUPTA
Sciences Practice Area
Leader and Principal
Gensler



JASON HAIDER
Founder and CEO
Xenco Medical



BRITTANY HEATH
Director of Clinical
Operations
Artemis Institute for Clinical
Research



SARAH HIBBARD
Associate
Snell & Wilmer



ERIK HOLMLIN
CEO and President
Bionano Genomics



ANGELA G. HUSKEY
Senior Vice President and
Chief Clinical Officer
Millennium Health



STEVE LAFLIN
Director of Customer
Success
Biosero, Inc.



SAMUEL LEVY
Chief Scientific Officer
Bluestar Genomics



**JAMES M.
MACKAY**
President and CEO
Artista Therapeutics



KYLE MANDALA
Manager
RSM US LLP



ROD MAZANDARANI
Director of Science and
Technology
Carrier Johnson +
CULTURE



GREG MCCLURE
Principal
Delawie



BARRY MERRIMAN
Chief Science Officer
Roswell Biotechnologies



PAUL MOLA
Founder, CEO and President
Roswell Biotechnologies



**SHAWNAH
MONTERREY**
Founder and CEO
BeanStock Ventures



JOHN M. NEWSAM
CEO
Tioga Research, Inc.



CHIP F. PARKER
President and CEO
LabX Ventures



RUTH PETERSEN
Senior Director of
Commercial Operations
Biosero, Inc.



TAMARA RANALLI
Senior Vice President,
Molecular Business Unit
Quidel Corporation



**KRITHI RAO
BINDAL**
President and Founder
Aroga Biosciences, Inc.




MATT RITTER
Senior Vice President,
Corporate Development
Equillum Inc



ANDREA SALAZAR
Chief Operating Officer
Biosero, Inc.



JANE SANDERSON
Director, Analytical
Development
Catalent Pharma Solutions
(San Diego Site)



JON SCAFFORD
Director, Engineering and
Continuous Improvement
Catalent Pharma Solutions
(San Diego Site)



RACHEL SOLOFF
Executive Director, Research
Kyowa Kirin, Inc.



SCOTT STROM
National Life Sciences Core
Market Leader
DPR Construction



CHARLES THEUER
CEO
TRACON



PELIN THOROGOOD
Cofounder/Executive Chair
Radicale Science



SUSAN TOUSI
Chief Commercial Officer
Illumina, Inc.



**STEPHANIE VENN-
WATSON**
Co-founder and CEO
Seraphina Therapeutics



**GAYANI R.
WEERASINGHE**
Owner
Law Offices of Gayani R.
Weerasinghe



**TIMOTHY
WESSELMAN**
CEO
Rosalind, Inc.



APRIL WURSTER
Counsel
Snell & Wilmer



DEBRA ZACK
Chief Medical Officer
Exagen



LILY ZHANG
Member
Mintz



DAVID ALIPOUR
CEO
AI Med Global

Navid Alipour is the Chief Executive Officer at AI Med Global, a company focused on artificial intelligence (AI) technology that improves healthcare and helps save lives.

AI Med Global is a rollup of two companies Alipour co-founded, CureMetrix and CureMatch. Prior, he founded La Costa Investment Group, making investments in early-stage startups.

Alipour is a long-time entrepreneur in the AI space, founding multiple companies with an emphasis on the convergence of AI and the life sciences – a model now referred to as “wellness science.”

Alipour identifies scientists who are experts in their respective fields and translates their research into viable businesses. He was part of the founding of Analytics Ventures and is a sought-after expert on the topics of venture capital and entrepreneurship for forums such as Venture Summit, MIT Forum, HeraHub, CyberHive, CONNECT and the U.S. News STEM Conference.

He can be reached at navid@analyticsventures.com or 949-637-0271.



STEPHANIE ALLEN
Director of Innovation Services
California Life Sciences

Stephanie Allen, Ph.D. is Director of Innovation Services at California Life Sciences (CLS). She has more than 25 years of experience as an industry scientist across drug discovery, medical devices, clinical and diagnostics research.

Prior to Allen's role at CLS, she founded Canvas Health and had been leading the translational science and strategic programs for development of proprietary molecular diagnostics in population health and genomic medicine. In her earlier work, she founded a stem cell research tool company and worked as a consultant helping early-stage technologies move from lab bench to market.

Allen serves on the National Committee for Women in Bio and Young Women in Bio and is a grant reviewer for the National Science Foundation.

Allen received her Ph.D. in molecular pathology at the University of California, San Diego.

She can be reached at SAllen@calife-sciences.org or 858-833-0025



JULIE AMES
Vice President
Biocom California

Julie Ames is Vice President of Corporate Communications at Biocom California.

Biocom California is the largest leader advocate for California's life science sector, working on behalf of more than 1,600 members to drive public policy, build a network of industry leaders, create access to capital and introduce cutting-edge STEM education programs.

Ames joined Biocom California in 2017 and is on the organization's statewide task force on Diversity, Equity and Inclusion. Prior to joining Biocom, she served as president and founder of The Cambridge Group, where she engaged in solving communications, leadership and public policy problems for a range of organizations.

Ames is on the Dean's Advisory Council at CSUSM College of Science, Technology, Engineering and Math, and the Executive Committee of the Board of Directors of the Mira Costa College Foundation.

She can be reached at Julie.Ames@biocom.org.



KATE BRODERICK
Senior Vice President, Research & Development
TriLink BioTechnologies

Dr. Kate Broderick is Senior Vice President of Research and Development at TriLinkBioTechnologies. She leads TriLink's research and development strategy and scientific direction at their research site in San Diego. TriLink, a MaravaiLifeSciences company, are leaders in the production of nucleic acids for research, diagnostics and therapeutics applications.

Broderick has in leading and liaising with multi-disciplinary groups from discovery and R&D to engineering and clinical teams. She brings broad scientific expertise to TriLink in multiple areas, including gene delivery, medical devices, gene therapies, cancer immunotherapies and vaccine development. She is a respected industry expert in the areas of DNA delivery and DNA based technologies.

In 2018, Broderick was named Business Women of the Year by San Diego Business Journal and in 2021 was named one of In Vivo's Rising Leaders.



MASSIMO CALAFIORE
Executive Vice President and Chief Commercial Officer
NuVasive

Massimo Calafiore is Chief Commercial Officer at NuVasive. He has helped shape and foster innovation at the largest spine-focused company in the world with more than \$1 billion in net sales—which, in turn, has helped further advance the global spine market with the advancement of less invasive surgery.

Calafiore has spent over 14 years dedicating his career to Life Sciences, joining NuVasive five years ago to first disrupt the limb lengthening and reconstruction orthopedic business with NuVasive Specialized Orthopedics. Since then, he's transitioned over to representing the entire spine business unit, overseeing both product marketing and commercial teams to help drive better spine surgery across the globe.

Calafiore is also an executive sponsor of NuVasive's first employee resource group, Women In NuVasive—a women-led organization focused on strengthening NuVasive by highlighting the value of diversity, inclusion, and engagement, while providing professional development opportunities for all employees.



ALLAN CAMAISA
Chairman and CEO
Calidi Biotherapeutics

Allan Camaisa is Chairman of the Board of Directors and CEO of Calidi Biotherapeutics.

After losing his own father to cancer, Camaisa became an early investor in Calidi, eventually leading the company in 2017. As Chairman and CEO, he has successfully led a \$32 million early-stage Series A round and has been actively involved in recruiting key board members and leading MDs and PhDs to the company's Scientific Advisory Board.

Camaisa uses his industry background to foster company growth, such as undertaking successful license negotiations with large pharmaceutical firms and facilitating the signing of a collaboration agreement with the National Institutes of Health.

During Camaisa's 30-year career as a serial entrepreneur, investor, and technologist, he has demonstrated proven leadership skills in bootstrapping startups. He has had four companies in the healthcare and technology sectors see successful exits, which were sold to publicly traded Fortune 1000 companies.

He can be reached at acamaisa@calidibio.com or 858-444-7059.



ENRIQUE CENICERROS
Director of Science + Technology
Taylor Design

Enrique Cenicerros is Director of Science & Technology at Taylor Design. He has dedicated his 30-year career to designing and planning life science facilities that incorporate sustainable design practices.

As a founding member and first president of the International Institute for Sustainable Laboratories (I2SL) Los Angeles/Orange County chapter, he promotes sustainable lab design practices throughout Southern California and beyond.

Cenicerros' career focus has been to creatively plan and design laboratories and life sciences facilities that most efficiently and cost-effectively meet the extensive requirements for health and environmental management, security, and resource consumption, ensuring that the next generation of laboratories addresses sustainable construction practices and contemporary standards of comfort, security, and safety.

Cenicerros gives back to the San Diego community through the Architecture Construction Engineering Mentor program and SoCal NOMA Project Pipeline, providing students with insight into building and design industries career paths.

He can be reached at ecenicerros@weare-taylor.com or 619-398-0450



JAIME D. CHOI
Partner, Co-Chair of Life Sciences and Medical Technology Industry Group
Snell & Wilmer

Jaime Choi, Ph.D. is Partner and co-chair of the Life Sciences and Medical Technology Industry Group at Snell & Wilmer – large business law firm practicing throughout the United States and in Mexico.

Choi's practice focuses on patenting complex, interdisciplinary technologies and building strategic patent portfolios, with an emphasis on evaluating and mitigating risk from third-party patents. She advises clients in a variety of market sectors, including bioinformatics, medical devices, microfluidics, photonics, advanced imaging and fabrication of complex materials and devices that use them. She also has deep experience in disputes, including litigation, arbitration, licensing, and trade secrets.

Within the start-up community, Choi has been involved in the Small Business Development Center at UCI Beall Applied Innovation, the USC Stevens Center for Innovation and the Zahn Innovation Center at the City College of New York, providing innovators with essential information on intellectual property needs.

She can be reached at jchoi@swlaw.com or 858-434-5014.



JEAN-CLAUDE CONSTANDSE
Principal
CPCArchitects

Jean-Claude Constandse is the Business Development & Marketing Principal and a founding partner of CPCArchitects. He is responsible for establishing, maintaining and improving client relationships. Over his has developed a wide range of multidisciplinary skills throughout his experience as a licensed architect with nbj and LPA.

Constandse is an expert in Life Sciences facilities design and construction in all phases of complex projects. Significant projects of his include the Millipore Sigma Bioreliance Viral & Gene Therapy Service Project and PD lab, the ThermoFisher Scientific MMS2 PD Lab expansion and the BBraun Microbiology lab expansion.

Constandse is a natural collaborator, bringing great energy to the development of ideas and processes which enable clients to realize their goals. He is experienced in all phases of the design and delivery of complex projects and is especially valuable to the team during the construction phase of a project.

He can be reached at Jean-Claude@cpccarchitects.com or 858-449-3066.



JAMI DEBRANGO-PALUMBO
Senior Vice President, Client Services and Operations
Foundation Medicine

Jami DeBrango-Palumbo is Senior Vice President of Lab Operations & Client Services at Foundation Medicine, Inc. She is a dynamic leader who had also served as the Vice President of Sequencing Operations.

Prior to that she was Vice President of the Roche Global Regulatory Complexity Management Program, a program focused on simplifying a complex network of global regulatory processes, which spanned more than 120 countries.

She joined Genentech in 2005 with the Biogen-Idec acquisition and has since served in roles of increasing responsibility, which span from HR, Facilities, Engineering, Supply Chain Operations and Safety, Health and Environment (SHE).

DeBrango-Palumbo has continued to take on senior leadership roles; her career journey includes roles such as Global Head of Project Management and Process Excellence, Pharma Technical Operations Biologics and President and Site Head for Roche Carolina Inc., a PT Small Molecules site.





Congratulations!

Krithi Rao Bindal, Ph.D., M.B.A.

President and Founder, Aroga Biosciences, Inc.

**and to the Aroga team on being selected as a Top Leader of
Influence in Life Science by San Diego Business Journal**

Krithi's experience and roles within the Pharma and Biotech industry have shaped her ability to deliver high-quality regulatory submissions in a broad range of therapeutic areas for local and global organizations alike.



Regulatory Medical Writing CRO
"Strength from Science"



www.linkedin.com/company/aroga-biosciences/



STEPHANIE CULLER
Co-founder and CEO
Persephone Biosciences

Stephanie Culler, Ph.D., is the co-founder and CEO of Persephone Biosciences, a business leveraging the systemic impact of the gut microbiome on the human immune system.

Persephone's technology platform is based on collecting and analyzing gut microbiota samples from thousands of healthy and diseased patients, then using machine learning and systems biology tools to understand the impact of gut microbes on patient prognosis. The results are used to design novel immunotherapies and companion diagnostics for diseases of unmet needs.

Culler is a graduate of the Y Combinator accelerator and has spoken at TEDx San Diego. Prior to establishing Persephone Biosciences, she was a senior scientist at Genomatica, where she applied synthetic biology toward engineering microorganisms as biocatalysts for commercial production of sustainable chemicals. She received her Ph.D. in Chemical Engineering from the California Institute of Technology and has over a 16 publications and patents on synthetic biology and microbial based technologies.



PETER DOWLEY
Senior Vice President, Investments,
San Diego & Life Science
Kilroy

Peter Dowley is Senior Vice President and Investments Lead of San Diego & Life Science at Kilroy Realty Corporation (KRC). He has been primarily focused on life science investment opportunities throughout the company's portfolio since joining Kilroy in 2018.

Dowley is responsible for helping to shape Kilroy's strategy in the life science space from an acquisition, leasing and development perspective, as well as leading the company's investment activity in the San Diego market.

At the helm of Kilroy's life science portfolio, Dowley has been most proud of his team's work to commence over \$1 billion of new life science focused development in 2021. Kilroy's rapidly expanding life science platform has bolted KRC into a leading position in the West Coast.

Prior to joining Kilroy, Dowley held progressive leadership roles with Strata Equity Group, Inc., BioMed Realty, and Ernst & Young.

Dowley also currently serves on the board of San Diego Downtown Partnership.



ARTHUR DEPTALA
CEO
Pathway NPI

Arthur Deptala is the CEO of Pathway NPI, medical device manufacturer impacting the future of healthcare.

Under his and his partner's leadership, Pathway NPI has become the leaders in early-stage medical device companies, enabling clients across the country to leverage its umbrella of certifications, audits and manufacturing technologies to expedite their time to market while focusing exclusively on selling their product. This solution in turn allows better use of startup capital and compresses the start-up timeframe.

To date, Pathway NPI has partnered with over 40 clients and designed and manufactured over 26 products.

Deptala has over 20 years of experience in developing innovative medical devices through all aspects of the product development life cycle and is uniquely skilled in leading engineering, quality control, regulatory compliance, and manufacturing teams.

He can be reached at adeptala@pathwaynpi.com or 619-339-1978



TOM GILMAN
President and CEO
Biosero, Inc.

Tom Gilman is founder and CEO of Biosero, Inc. He is a changemaker in the life science industry, motivating biotech and pharmaceutical companies to integrate automation technology that accelerates scientific discovery. He drives the overall commercialization strategy and team development at Biosero, founded in 2003.

One of the premier automation software providers in the life science industry, Biosero rapidly develops innovative software solutions that enable scientists, researchers and technologists to use automation successfully every day.

For more than 30 years, Gilman has delivered on the promise of automation in the lab as a manager at Beckman and IGEN, and subsequently as an executive at HCG and Apricot Designs, by coaching customers on how to solve complex workflow challenges.

Under Gilman's leadership, Biosero achieved its best financial year ever in 2021, even after giving away millions of dollars' worth of our software for free to labs contributing to the fight against COVID-19.



TOM GIUGGIO
Vice President and Senior Lab
Planner
HKS Architects

Tom Giuggio is Vice President and Senior Lab Planner at HKS Architects.

He started his career at Earl Walls Associates in 2001. Earl Walls Associates grew from a 1962 collaboration between Dr. Jonas Salk, architect Louis I. Kahn and founder Earl Walls to designed the Salk Institute, which established new milestones for laboratory facilities design.

Giuggio's over 20 years of experience includes planning highly technical laboratory buildings for clients in the government, education, health and commercial sectors. He works closely with lab users, engineers and general contractors, developing custom details and researching special applications of materials and equipment to achieve client goals. Recent projects include the U.S. Food and Drug Administration, Wexford Biomedical Campus Building 1, Pfizer CB-10 Laboratory, Naval Medical Center San Diego Renovation and Emory Executive Park Musculoskeletal Institute.

He can be reached at tgiuggio@hksinc.com or 858-397-5564.



ARISTEA

THERAPEUTICS

We would like to congratulate, **James Mackay**, CEO and Founder at Aristea Therapeutics, for being recognized as one of the Top 50 Leaders in Life Sciences by the San Diego Business Journal. This award celebrates trailblazers, entrepreneurs and innovators in life sciences who have created a long-lasting impact in the field and our community here in San Diego



**Striding to the forefront of innovative
therapeutic options for inflammatory diseases**

12770 High Bluff Drive, Suite 380
San Diego, CA 92130
aristeatx.com



**SMITA GUPTA**

Sciences Practice Area Leader and Principal
Gensler

Smita Gupta is Southwest Sciences Practice Area Leader and Principal at Gensler. Her over 25-year career with Gensler spans from workplace design, strategic consulting and leading the development of the firm's India operations, to being a Director of Client Relations in the Asia, Pacific, India, and Middle East Region.

Gupta's experience as a senior strategic facilities planner for Genentech positions her to grow Gensler's sciences practice in San Diego and throughout the Southwest region. Her attention to detail and coordination skills leads to successful projects and to excellent relationships with clients, consultants and contractors. She has worked with more than five local biopharma companies and developers in San Diego to help support them with real estate and science workplace solutions.

Gupta is a current member of ULI India and is proactively working to join a ULI Council and be a member of ULI San Diego. She is also involved with Bio-com and California Life Sciences.

Gensler

**JASON HAIDER**

Founder and CEO
Xenco Medical

Jason Haider is the founder and CEO of Xenco Medical, a medical device company.

Under Haider's leadership, Xenco Medical has introduced a new category of surgical implant systems with its sterile-packaged spinal implants pre-attached to disposable, composite polymer delivery instruments. Xenco Medical's surgical devices have been found to save hospitals across the U.S. up to \$1,100 per surgery by eliminating the expensive processes associated with the sterilization and transport of reprocessed instruments and implants.

Haider also spearheaded the company's presence in specialized surgical markets through the development of Xenco Medical's ASC CerviKit platform for ambulatory surgery centers and the company's Wi-Fi-enabled surgical vending machines for real-time monitoring of Xenco Medical's surgical implant inventory.

Outside of his work at Xenco, Haider has served on the board of directors of the California Workforce Development Board since being appointed to the position in 2018 by Gov. Jerry Brown.

**BRITTANY HEATH**

Director of Clinical Operations
Artemis Institute for Clinical Research

Brittany Heath is Director of Clinical Operations at Artemis Institute for Clinical Research.

In the six years she has been at Artemis, Heath started as the site manager of two locations, San Marcos and Riverside. She started both sites from the ground up, hiring all the employees; performing business development activities to ensure sponsors would allow us to perform trials at those locations; and ensuring Artemis was able to recruit patients successfully to those locations.

When she was promoted to director in 2019, Heath was responsible for leading all of the company's clinical research sites across Southern California. She is now focused on implementing new changes that will allow Artemis Research to grow and scale as efficiently as possible.

During her tenure, Heath has led the Artemis Research Team to two Pharma Times first place awards as the Clinical Research Site of the Year in 2018 and 2020 - a national competition.

**SARAH HIBBARD**

Associate
Snell & Wilmer

Sarah Hibbard is an Associate at Snell & Wilmer.

As a Snell & Wilmer corporate and securities attorney and former in-house general counsel for a San Diego-based biotechnology company operating in the oncology space, Hibbard counsels life sciences and technology companies from formation through growth and exit, serving as a strategic advisor in the journey from research and development to commercial success.

Hibbard draws on stealth start-up to multibillion-dollar company insights to serve life science and technology clients, blending legal strategy, and planning with practical solutions. As a dealmaker, she represented companies on venture financings, licensing and tech transfers; collaborations; sponsored research and clinical research; and commercial transactions, as well as mergers and acquisitions.

Hibbard is co-vice chair of Founder's Forum for the San Diego Chapter of Women in Bio. She is a member of Athena, Women in STEM and the Licensing Executive Society San Diego Chapter. She can be reached at shibbard@swlaw.com or 858-434-5004.

Snell & Wilmer

**ERIK HOLMLIN**

CEO and President
Bionano Genomics

Erik Holmlin is President and CEO of Bionano Genomics - provider of optical genome mapping systems, software, testing and laboratory services. The company is a leader in structural variation analysis, which improves diagnosis and treatment for genetic disease and cancer.

Since 2020, Holmlin has led Bionano's expansion from 85 to 323 employees, with revenue growth of 111% from 2020 to 2021, and the successful acquisitions of software solutions company BioDiscovery, and genetics diagnostic company Lineagen.

Holmlin has more than two decades of experience developing innovative solutions and companies in the life sciences and health care industries. He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

Holmlin has been director or advisor on company boards, including GenVault, Astute Medical, Xagenic, and NanoSphere. He is currently on the board of ILAC and the board of the Medical Research Organization of the Ahmansen-Lovelace Brain Mapping Center at UCLA.




With 20+ years of experience, BeanStock Ventures offers professional guidance and services in medical device software product development and regulatory compliance.



EXPERTS IN MEDICAL DEVICE

**BREAKING GROUND
AND REACHING NEW
HEIGHTS**



Shawannah Monterrey
CEO, Founder
BeanStock Ventures



marketing@beanstockventures.com
www.beanstockventures.com



833.688.BEAN (2326)



8885 Rio San Diego Dr., #237
San Diego, CA 92108

**ANGELA G. HUSKEY**

Senior Vice President and Chief
Clinical Officer
Millennium Health

Angela G. Huskey is Chief Clinical Officer at Millennium Health.

After caring for a loved one with substance use disorder (SUD), Huskey made it her mission to improve the care of patients suffering from pain, mental illness and addiction.

Huskey is on the frontlines of creating change as our nation faces the critical public health problem of drug overdose deaths. She recognized the opportunity to engage her team in harnessing data available through Millennium's analytics platform to create trend reports identifying emerging drug threats.

Using drug test results to monitor the shifting landscape of drug use allows clinicians, first responders and those responsible for public health to be informed about these changes to help prevent overdoses and save lives. National and state agencies have reached out to Huskey to explore potential partnerships and multiple manuscripts have been published to further educate the health care community about evolving substance use trends.

**STEVE LAFLIN**

Director of Customer Success
Biosero, Inc.

Steve Laflin is Director of Customer Success at Biosero, Inc. His focus is on improving human health and quality of life through software innovation.

Laflin's passion for next-generation technology is reflected in his thought leadership and collaborations on the design and development of lab-of-the-future technology. He has been a guest speaker at both conferences and board of directors' meetings. His innovative ideas have been used both internally and externally for over 20 years.

Laflin is a many times nominee and recipient of the Lilly Top 100 Innovators. As a senior director at Lilly, he worked with all levels of management, automation teams, IT, operations, facilities, finance, procurement and researchers to integrate these new technologies within Lilly labs globally.

Prior to his role at Lilly, Laflin served in roles supporting manufacturing, research and development, facilities, health, safety, and environmental, capital management, and global-shipping logistics.

**SAMUEL LEVY**

Chief Scientific Officer
Bluestar Genomics

Samuel Levy, Ph.D. is Chief Scientific Officer at Bluestar Genomics, a provider of non-invasive epigenomic tests to detect cancer earlier than existing methods and when the disease is still treatable.

Levy has extensive background and experience in the application of genomic methods for the development of molecular diagnostic tests. He joined Bluestar Genomics at its inception and has co-authored many of the research papers the company has published about its epigenomics technology platform and DNA-based 5-hydroxymethylcytosine (5hmC) biomarker.

Previously, Levy held leadership positions in genomics and molecular diagnostic development companies including Celera, Genomic Health, Quantice Pharmaceuticals (now part of Celgene), and Impact Genomics/Lexent Bio, which he co-founded and is now a part of Foundation Medicine.

Levy also served on the faculty at the J. Craig Venter Institute, Scripps Translational Science Institute, and Scripps Research Institute.

**JAMES M. MACKAY**

President and CEO
Aristea Therapeutics

James M. Mackay, Ph.D., is President and CEO of Aristea Therapeutics.

Prior to Aristea, Mackay was President and CEO of Ardea Biosciences during the company's \$1.26 billion acquisition by AstraZeneca. He grew Ardea by 70% and led the team through FDA and EMA approvals for Zurampic and Duzallo, the first novel mechanism treatments for gout in over 50 years. Prior to that, Mackay held senior leadership positions at AstraZeneca, including Global Product Vice President for both the gout and diabetes franchises, as well as many other senior roles there.

In addition to leading Aristea, Mackay is active on the boards of CONNECT and Biocom and is a past board member of the San Diego Economic Development Corporation. He is also on the board of advisors and a financial supporter of Life Science Cares - San Diego—a collective effort of the local life sciences industry to reduce the impact of poverty in the San Diego community.

**KYLE MANDALA**

Manager
RSM US LLP

Kyle Mandala is Manager at RSM US LLP. He is a first-generation college graduate, earning his degree from UCSD. In 2014, he was the first college direct hire for the West Region Technology and Management Consulting Practice at RSM, the U.S. member of RSM International, a global network of independent audit, tax and consulting firms.

Mandalawas elected the Life Sciences national industry leader for RSM's NetSuite practice, where he redesigned industry methodology and under his leadership, has grown revenues fivefold. He also grew his Southern California NetSuite team to 14 consultants.

Recently, Mandala was nominated and selected to attend the RSM Owners Meeting as a Futuremaker, a firmwide program for high performing managers defined as "a person responsible for making the future happen and inspire others to do the same." And effective Aug. 1, he is promoted to the position of Director.

He can be reached at kyle.mandala@rsmus.com or 619-516-1105.



CONGRATULATIONS

TO BIONANO GENOMICS

AND PRESIDENT & CEO

ERIK HOLMLIN

for being recognized among
the top 50 Biotech Companies
and Top 50 Leaders of
Influence in Life Science.



TRANSFORMING THE WAY THE WORLD SEES THE GENOME

bionanogenomics.com



ROD MAZANDARANI
Director of Science and Technology
Carrier Johnson + CULTURE

Rod Mazandarani is Director of Science & Technology for Carrier Johnson + CULTURE, a global architecture firm. Mazandarani has a degree in Integrative Arts & Philosophy from Penn State University, College of Arts & Architecture, and a Master of Architecture degree from New School of Architecture & Design. Mazandarani was an early recipient of the LEED Accredited Professional designation in 2003. He is an industry pioneer in sustainability practices for high-performance facilities. His talent for green lab planning helped create some of the world's best STEM buildings, including work at the Lawrence Berkeley National Laboratory, and the recent Kuwait University College of Science Complex, which features over 1 million square feet of laboratory facilities. Mazandarani is a mentor in the ACE Mentor Program, a long-time volunteer for the San Diego Food Bank, and a tutor for English as a Second Language (ESL) students throughout the local community. He can be reached at ram@carrierjohnson.com or 619-916-7793.

carrierjohnson + CULTURE



GREG MCCLURE
Principal
Delawie

Greg McClure is Principal and Life Science studio leader and Senior Lab Planner with Delawie. He is responsible for establishing Delawie's lab standards and mentoring the staff of architects and designers and is an integral part of the life science community in San Diego, supporting a variety of clients in establishing and expanding their footprint in the region. McClure's breadth of experience includes the award-winning, 250,000 square-foot, four-building BioLegend campus, as well as the Nitto Denko project in Oceanside. He is involved with over a dozen existing building conversations to life science and speculative labs for several developers with projects such as Sterling Bay West, BioMed Reality and 5-Ronin. As Principal-in-Charge, McClure has supported numerous ground-up speculative laboratory core and shell designs including Intersection Real Estate and BioScience Properties. He is an integral part of Delawie's tenant-specific laboratory tenant improvement projects with a variety of valued clients involving AlvaMab, Exagen and Illumina.



BARRY MERRIMAN
Chief Science Officer
Roswell Biotechnologies

Barry Merriman, Ph.D. is co-founder and Chief Science Officer of Roswell Biotechnologies. He has more than 30 years' experience in scientific research and technology development, with deep expertise in DNA sequencing technology and associated applications. Previously, Merriman was vice president of global technology assessment at Human Longevity, Inc., working with Craig Venter to create the technology stack for a comprehensive approach to precision medicine and oncology. Merriman was also chief science officer of the Enterprise Genomics Solutions Business at Life Technologies where he architected the future sequencing technology roadmap for the company, including programs resulting in the acquisition of Ion Torrent sequencing platform and engagement with the Genia sequencing platform. He also architected population-scale genome sequencing programs globally, including the national program for the government of Saudi Arabia. Merriman served on the faculty of UCLA for 20 years.



PAUL MOLA
Founder, CEO and President
Roswell Biotechnologies

Paul Mola is founder, CEO, and President of Roswell Biotechnologies. Previously, he was Head of Global Solutions at Human Longevity, Inc., working to establish international precision medicine partnerships. Prior to that, Mola spent over a decade at Life Technologies / Applied Biosystems where he was president of the Enterprise Genomic Solutions Business Unit and head of strategy and chief of staff for the Genetic Systems Division managing strategy and international, large-scale business engagements for the DNA Sequencing Technology portfolio. Mola received Life Technologies' Game Changer Award for accomplishments including establishing Saudi Arabia's national genome sequencing program, driving the acquisition of the Ion Torrent sequencing platform, leading the commercialization of the SOLiD sequencing platform, and developing the business strategy for the Genia sequencing platform. Mola serves on the board of Biocom California.



SHANNAH MONTERREY
Founder and CEO
BeanStock Ventures

Shannah Monterrey is founder and CEO of BeanStock Ventures, a medical device product development company. BeanStock is one of nine FDA accredited 510(k) review organizations. The company utilized 2020 to establish new products and strengthen its foundations and proceeded to double in size in 2021 and has since secured long-term partnerships with numerous Fortune 500 companies. Monterrey founded BeanStock Ventures in 2018 following a 20-year career as a technical leader responsible for developing strategies and leading complex global product development programs and functional management of software engineering and software quality assurance departments for both startup and mature organizations. She has held technical leadership roles at Illumina, Covidien (Medtronic), Invetech (DanaHER) and Carl Zeiss Meditec. Monterrey is a member of the National Institute of Health (NIH) Commercialization Readiness Pilot Special Emphasis Review Panel.



CONGRATULATIONS

Tamara Ranalli, Ph.D

SVP, Molecular Business Unit, Quidel Corporation



2022 Top 50 Leader of Influence in Life Science



We're grateful for your leadership and for your commitment to shaping the future of Life Science in San Diego.



QUIDEL

Advancing Diagnostics to Improve Human Health



JOHN M. NEWSAM
CEO
Tioga Research, Inc.

John M Newsam is CEO of Tioga Research, Inc. He has led Tioga Research to further successes in delivering contract services in the R&D of skin-applied formulations, including topical and transdermal pharmaceuticals and personal care products.

As a consultant, Newsam contributed scientific and strategic input to Fortune500 companies, early phase biotech and materials companies and to government institutions such as IFP Energies Nouvelles. As a business innovator and entrepreneur, Newsam has served as a founder or co-founder of Permeatus, DMK Pharmaceuticals, Tioga Research, Bio4Front, Windhover Ventures and many, many more.

Newsam has delivered undergraduate courses on entrepreneurship and business innovation at UC San Diego and has been an adjunct professor at both UC Santa Barbara (Materials Department) and UCSD (Chemistry & Biochemistry Department).

He can be reached at info@tiogaresearch.com or 858-202-1569.



CHIP F. PARKER
President and CEO
LabX Ventures

Chip F. Parker is President and CEO of LabX Ventures. He has over 30 years of C-Suite experience in start-ups and emerging growth companies in both technology and life sciences, including business development, operations, sales, marketing, management and publishing in addition to capital formation and board-building.

With years of experience as a founder/operator, early-stage investor and syndicator, Parker understands both the investor's perspective and entrepreneur's pain points of starting, funding and building an enterprise class company.

Parker is the chief architect of the "Venture Science" and "New Venture Predictive Analytics" disciplines. The over 10 years of development and beta testing of this analytic has included contributions from and cooperation with Qualcomm, Bell Labs, Price Waterhouse Cooper, Alcatel-Lucent Ventures, The University of Texas IC2 Institute and Wilson Sonsini.

He can be reached at cparker@labxventures.com or 949-636-5655.



RUTH PETERSEN
Senior Director of Commercial Operations
Biosero, Inc.

Ruth Petersen is Senior Director of Commercial Operations at Biosero, Inc. She is passionate about making life sciences and laboratory automation accessible. She leverages her extensive knowledge of technology to bridge the gap between engineering and science.

Over the last 20 years, Petersen has been an influential contributor in some of the most innovative companies in the industry. Before joining Biosero, she held leadership roles at gene synthesis pioneer Codex DNA, Inc., lab automation firm Labcyte, Inc., and Agilent Technologies. She has also worked in applications development and support at Velocity11 and Aurora Discovery, Inc., and as an engineer at Vertex Pharmaceuticals and Aurora Biosciences Corp.

Petersen is active in Women of the Society for Laboratory Automation and Screening Laboratory Research and Innovation Group and Girl Scouts of the USA.

She can be reached at ruthpetersen@biosero.com or 619-838-3445.



TAMARA RANALLI
Senior Vice President, Molecular Business Unit
Quidel Corporation

Dr. Tamara Ranalli is Senior Vice President of the Molecular Diagnostics Business Unit for Quidel Corporation, an industry-leading manufacturer of diagnostic solutions.

Ranalli joined Quidel in 2010 from BioHelix Corporation. Since joining Quidel, Ranalli has played a pivotal role in the conceptualization and development of industry-defining diagnostics technologies. Her contributions have been felt globally due to her work developing some of the first molecular COVID-19 diagnostic tests to receive Emergency Use Authorization from the FDA in early 2020.

More recently, Ranalli has played an integral role in the development of Savanna, a PCR testing platform capable of detecting up to 12 pathogens from a single sample in less than 25 minutes.

In her executive role, Ranalli's focus is on defining and executing the strategic vision for Quidel's diagnostic portfolio, including development initiatives, product offerings and partnering strategies.



KRITHI RAO BINDAL
President and Founder
Aroga Biosciences, Inc.

Krithi Rao Bindal is the President and Founder of Aroga Biosciences, a pharmaceutical firm that specializes in regulatory writing and regulatory submission services from drug discovery to launch.

Bindal is passionate about science and technology advancement and makes it a priority to bring together partners and an expert team of women scientists to advance technology development and effectively communicate science. She is driven by enhancing diversity in the technology space and believes San Diego is an optimum location for this growth.

Bindal was selected as the "Face of Biotechnology Development" in 2021 and 2022 by San Diego Magazine. Faces of San Diego highlights San Diego innovators who use their expertise to elevate their fields and bring big ideas to life. Bindal also led Aroga Biosciences to prominence this year when the company was selected as a Top 10 CRO of 2022 by PharmaTech Outlook Magazine.

She can be reached at kbindal@arogabio.com or 858-925-6145.



CONGRATULATIONS,
KYLE MANDALA

RSM is pleased to announce that our colleague, **Kyle Mandala**, has been selected as a finalist for San Diego Business Journal's **2022 Top Leaders of Influence in Life Science**.

THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING



RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax and consulting firms. Visit rsmus.com/aboutus for more information regarding RSM US LLP and RSM International.



MATT RITTER
Senior Vice President, Corporate Development
Equillum Inc

Dr. Matt Ritter, Ph.D., is Senior Vice President, Corporate Development at Equillum Inc. Ritter joined Equillum from La Jolla Pharmaceutical Company where he was head of business development and responsible for all business development, licensing, M&A and alliance management activities. Prior to La Jolla Pharmaceutical, he held leadership roles in the business development group at the Scripps Research Institute where he was responsible for strategic alliances, licensing, company formation and intellectual property management. Ritter was the recipient of an NIH National Research Service Award during his postdoctoral fellowship at the Scripps Research Institute, obtained his Ph.D. in biochemistry and molecular biology from the Keck School of Medicine at the University of Southern California and his B.S. in biological sciences from the University of California, Irvine. He can be reached at mritter@equillumbio.com or 858-210-1390.



ANDREA SALAZAR
Chief Operating Officer
Biosero, Inc.

Andrea Salazar is Chief Operating Officer for developing and maintaining a seamless experience among the company, its customers and numerous business partners. Salazar helped grow the company from four team members in 2011 to 102 employees worldwide in 2021. She is also responsible for designing Biosero's pricing and sales commission structures, contributing to a double-digit increase in profitability. She created and executed Biosero's Employee Stock Option Plan and is currently heading up the implementation of an Enterprise Resource Planning (ERP) within the company. Salazar has been instrumental in the launch of Biosero's "WHY" project, an annual initiative that provides monetary awards to charities selected by the Biosero employees. In late 2021 Salazar lead the merger and acquisition team which resulted in the successful sale of Biosero to BICO, a Swedish company focusing on the convergence of biology and technology. She can be reached at andreasalazar@biosero.com.



JANE SANDERSON
Director, Analytical Development
Catalent Pharma Solutions
(San Diego Site)

Jane Sanderson is Director of Analytical Development at Catalent Pharma Solutions, San Diego. She is a laboratory services scientist and executive with over years of experience leading key growth initiatives in the pharmaceutical industry and is known as an expert in delivering innovative, reliable, cost-saving quality control solutions and implementing operational strategies to streamline processes while meeting changing business needs. Sanderson leads a team of 20 scientists in development and application of analytical methods and transformed Catalent's analytical labs and processes into a unique offering that customers have become very pleased with and accustomed to. Because of Sanderson, her area of expertise has recently been dedicated an entire building – with future CAPEX construction – to expand her analytical team and capacity. Sanderson is a member of Biocom, the North San Diego Business Chamber, North County Philanthropy Council and is also an invited member of the Fellow of the Royal Society Chemistry.



JON SCRAFFORD
Director, Engineering and Continuous Improvement
Catalent Pharma Solutions (San Diego Site)

Jon Scrafford is Director, Engineering and Continuous Improvement at Catalent Pharma Solutions, San Diego. He is a seasoned engineering professional with 12 years of scientific and engineering experience in the pharmaceutical and biotech sector. At Catalent, Scrafford leads an engineering team of 15. Some of their responsibilities include equipment validation, CapEx, equipment repair and modification R&D pharmaceutical batch production. He created an innovative QR code system for employees to easily contribute innovative ideas to improve the site, and to report safety concerns in the laboratories and manufacturing spaces. He also co-leads an employee program at Catalent San Diego called SLAM (Skills, Leadership and Management), which focuses on professional development through books, podcasts, and discussion groups. Scrafford plays a critical role in educating and influencing critical clients that are creating therapeutic drugs for Covid-19, Cancer, Parkinson's disease, and others.



RACHEL SOLOFF
Executive Director, Research
Kyowa Kirin, Inc.

Dr. Rachel Soloff is Executive Director of Research at Kyowa Kirin, Inc. She oversees the Kyowa Kirin U.S. drug discovery research activities focusing on immunology and the discovery of novel monoclonal antibodies and small molecule therapeutic compounds for autoimmune and inflammatory diseases. Utilizing innovative antibody technologies, Kyowa Kirin has been able to consistently maintain a pipeline of novel therapeutics to treat a wide variety of disorders. Soloff was featured as a groundbreaking woman scientist in BioSpace Magazine in a June 2021 article titled "Tilting At Gender Equality at the Highest Levels." She was also featured with her colleague Dr. Andrew McKnight in the Hopkins Biotech Podcast, "Pioneering Monoclonal Antibody Discovery and Development." Soloff champions collaboration in her labs and is considered by her colleagues to be one of the best leaders they've worked with and nominated and is under consideration for a 2022 Ignite Respect Award from the Center for Respectful Leadership.



TAYLOR design
DESIGN THAT EMPOWERS PEOPLE
wearetaylor.com



CONGRATULATIONS
ENRIQUE CENICERROS
AND OUR LIFE SCIENCES STUDIO

Taylor Design is a 100% employee owned firm, ENR Top 500, and Best Firm to work for 4 years running

Architecture | Site Planning | Laboratory Planning
Interior Design | Feasibility Studies | Test Fits





SCOTT STROM
National Life Sciences Core
Market Leader
DPR Construction

Scott Strom is National Life Sciences Core Market Leader for DPR Construction. DPR is one of the country's top technical builders and No.1-ranked pharmaceutical contractor in the U.S. according to the ENR Top Contractors List 2021.

Storm's expertise is in project costs and design standards for both lab and manufacturing facilities in institutional and corporate projects. Since joining DPR in 1993, He has built strong relationships with industry-leading life science customers. He works with regional core market experts and account leaders to help DPR excel in the life sciences core market, which is focused on understanding and better serving customers in the areas of biotechnology, pharmaceutical, bio-agricultural, medical device and research institutes.

Storm holds a Bachelor of Science in Construction from Texas A&M University and is a USGBC LEED 2.1-Accredited Professional. He has served on the board of directors at YMCA-Ecke Branch and participated in the annual Baja Challenge to build homes for impoverished families.



CHARLES THEUER, M.D.
PH.D.
CEO
TRACON

Dr. Charles Theuer is President, CEO, and Board Member of TRACON Pharmaceutical.

His work is aimed at transforming outcomes for cancer patients by helping pharmaceutical companies streamline the costly and lengthy process of research and development. Through their Product Development Platform, TRACON Pharmaceuticals reduces the cost and time of drug development without compromising on the rigorous standards demanded by the FDA.

Theuer is author of "Unnecessary Expense: An Antidote to the Billion Dollar Drug Problem," published by ForbesBooks, about the \$2 billion estimated cost to approve each new drug, a cost that companies offset with premium pricing.

As CEO at TRACON Pharmaceuticals, Theuer opened 29 U.S. cancer centers to enroll sarcoma patients into the ENVASARC clinical trial.

Theuer is also a board member for SD Square. He can be reached at ctheuer@tracopharma.com or 858-251-3490.



PELIN THOROGOOD
Cofounder/Executive Chair
Radicle Science

Pelin Thorogood is co-founder and Executive Chair of Radicle Science.

She is a data executive turned impact entrepreneur who made a career of being at the forefront of emerging trends and disruptive technologies. With a focus on data and analytics throughout her career, Thorogood is now on a mission to democratize precision medicine as through Radicle Science which is generating the first proprietary datasets that can prove and predict the effects of health and wellness products.

Previously, Thorogood served as CMO of WebSideStory and CEO of predictive analytics company Anamatrix, both headquartered in San Diego.

Thorogood is also co-founder and president of the Wholistic Research and Education Foundation; trustee and treasurer of the UC San Diego Foundation; executive board member of the UCSD Basement start-up incubator and Industry Scholar for the Cornell Institute of Healthy Futures.

She can be reached at pelin@radicle-science.com.



SUSAN TOUSI
Chief Commercial Officer
Illumina, Inc.

Susan Tousi is Chief Commercial Officer at Illumina, Inc. She reports directly to the CEO and is responsible for Illumina's global sales, commercial operations and commercial strategy. She joined Illumina in 2012 and previously lead the product development organization as Chief Product Officer. Under her leadership, Illumina has launched industry leading sequencing platforms and achieved the most expansive product portfolio in the company's history, including the NovaSeq Series, a scalable sequencing architecture expected enable a \$100 genome.

Tousi led the acquisition of Edico Genomics, BlueBee and Enancio. Combined with Illumina's existing software solutions, these new capabilities enable scalable, seamless, end-to-end software solutions that drive the utilization of genomic data and accelerate the adoption of genomic data in clinical care.

Tousi was elected to the National Academy of Engineers in 2018; named one of the 50 Top Diverse Leaders for 2020 by the California Diversity Council; and is a member of the International Women's Forum.



STEPHANIE VENN-WATSON
Co-founder and CEO
Seraphina Therapeutics

Stephanie Venn-Watson, DVM, MPH, is a veterinary epidemiologist and the co-founder and CEO of Epitracker and Seraphina Therapeutics.

While studying the health of long-lived Navy dolphins, Venn-Watson found the first essential fatty acid to be discovered in 90 years, pentadecanoic acid (C15:0). It is now believed that nutritional deficiencies in C15:0 may be contributing to the global pandemics of diabetes, heart disease and liver disease. Following this discovery, Seraphina developed the only patented C15:0 ingredient and supplement on the market, FA15TM and fatty15, containing a pure, vegan-friendly form of C15:0.

Venn-Watson co-founded the National Marine Mammal Foundation. She also founded STEM education program Gap Junction and health education program Healthy Pets, Healthy People. She was awarded an Albert Schweitzer Fellow for Life as well as the Department of Health and Human Services Secretary's Award for Disease Prevention and Health Promotion.



BCG is proud to recognize and celebrate the Top 50 Leaders in Life Science 2022!

Our San Diego teams (and a new office downtown) are here to unlock the potential of the people, organizations, and industries that power our city and community.



For more information, please visit bcg.com to see how we can work together to address the most critical challenges facing your company today

401 W. A St. | jager.jason@bcg.com | 619 894 7103



Navid Alipour
CEO of AI Med Global

AI TECHNOLOGY THAT IMPROVES HEALTHCARE AND HELPS SAVE LIVES



aimedglobal.com

**GAYANI R. WEERASINGHE**

Owner
Law Offices of Gayani R.
Weerasinghe

Gayani Weerasinghe is owner of Law offices of Gyani R. Weerasinghe. She is a business law and intellectual property (IP) attorney with both law firm and in-house experience and has a strong life science background. Before becoming an attorney, she was actively involved in biomedical research at the National Institutes of Health in Bethesda, Maryland for nine years.

Weerasinghe's practice focuses on helping businesses with their transactional needs, including providing part-time general counsel services to biotechs and startups, drafting and negotiating many different agreements and registering trademarks.

Weerasinghe is active with many local bar organizations and business communities. She is the current co-editor of San Diego Lawyer Magazine, immediate past president of Women In Bio (WIB) Southern California Chapter and recognized as a Super Lawyer Rising Stars since 2020.

She can be reached at gayani@lawgrw.com or 858-247-1886.

GRW

**TIMOTHY WESSELMAN**

CEO
Rosalind, Inc.

Tim Wesselman is founder and Chief Executive Officer of Rosalind, Inc., an industry-leading life sciences company that is out to streamline, simplify and revolutionize the way we currently analyze and store genomic data. Wesselman believes that software innovation will allow scientists to be in more control of their own research, enabling them to unlock the deeper mysteries of biology.

Under Wesselman's leadership, Rosalind spearheaded the variant-calling and tracking system for the National Institutes of Health to support the United States' monitoring of Covid-19 diagnostic efficacy for the White House's RADx program and the FDA. He also he doubled the company's headcount in San Diego during a time when others were laying off in the industry.

Before Rosalind, Wesselman served as vice president for Hewlett-Packard's Global Enterprise Solutions Business. He is a graduate of multiple programs from Columbia University, Rice University, University of Michigan and Texas A&M University.

He can be reached at tim@rosalind.bio or (858) 683-9042.

ROSALIND
DATA MADE HUMAN

**APRIL WURSTER**

Counsel
Snell & Wilmer

April Wurster is Counsel at Snell & Wilmer. She focuses her practice in intellectual property and life science and uses cross-functional knowledge and experience to build a thorough understanding of the company's business, employees, products, customers and competitors to provide strategic guidance.

Wurster works in new subject matter areas daily, assimilates information quickly and develops a deep understanding in those areas. She excels at distilling complex ideas into understandable concepts. Her patent protection experience includes working with inventors to identify patentable inventions, drafting patent applications, prosecuting patents and providing freedom to operate analyses. Her trademark protection experience includes assisting clients with filing and prosecution, as well as ensuring proper trademark usage on product marketing materials.

Additionally, Wurster is involved with Athena, Women in Bio and SunLaw. She can be reached at awurster@swlaw.com or 858-434-5011.

Snell & Wilmer

**DEBRA ZACK, M.D.**

Chief Medical Officer
Exagen

Dr. Debra Zack, M.D., Ph.D. is Chief Medical Officer of Exagen.

She has worked in life Sciences for 22 years and is a board-certified rheumatologist with extensive experience as a biopharmaceutical executive in the development of therapeutics for autoimmune disease. At Exagen, she oversees the strategy and execution of clinical development and is passionate about her work leading research and medical affairs teams focusing on autoimmune disorders.

Prior to joining Exagen, Dr. Zack served as vice president of clinical development at Xencor, Inc.; as executive director and medical scientific leader of the Biotherapeutics Development Unit at Novartis; and various positions in research and clinical development at Amgen. She was an associate professor treating rheumatology patients for 10 years at UCLA prior to joining industry.

Dr. Zack received her undergraduate degree from Texas Christian University, her M.D. and Ph.D. from the University of Texas Southwestern and completed her residency at the UCLA School of Medicine.

Exagen
Patient Focused. Discovery Driven.

**LILY ZHANG**

Member
Mintz

Lily Zhang is a Member at Mintz. She is an IP practitioner specializing on patent preparation and prosecution and on providing clients with strategic insights in portfolio management.

What sets Zhang apart from her peers is her rare combination of exceptional client service and collaboration, in-depth expertise in emerging/evolving areas of technology, such as AI and machine learning, and enthusiasm for new and innovative approaches to patent strategy and prosecution. She digs into her clients' technologies to fully understand the commercial markets for the technology, the relevant enforcement regimes and effective monetization schemes.

In acknowledgement for her outstanding work Zhang has been recognized as one of San Diego Business Journal's Women of Influence in Technology, Next Top 40 Business Leaders Under 40 and Top 50 Women of Influence in Law in San Diego.

She can be reached at LZhang@mintz.com or 858-314-1577.

MINTZ

SAN DIEGO BUSINESS JOURNAL

**LEADERS
of INFLUENCE**

LIFE SCIENCE

TOP 50

2022

HONOREE

We at Exagen are excited to congratulate our Chief Medical Officer, **Dr. Debra Zack**, on being selected as an honoree for the Top Leaders of Influence in Life Science!

Exagen®

Patient Focused. Discovery Driven.
888.452.1522 or info@exagen.com

Congratulations

to our Chief Clinical Officer

Angela G. Huskey, PharmD, CPE on her extraordinary achievements and for being recognized as a **Top Leader of Influence in Life Science!**

**MILLENNIUM
HEALTH**

www.millenniumhealth.com



Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Arcturus Therapeutics



arcturusrx.com



TOP 50 LEADERS IN LIFE SCIENCES

Congratulations to CJ+C's Director of Science & Technology, **Rod Mazandarani**, on this well-deserved recognition! We are proud to have you represent our firm and of your impact in the life sciences field. Cheers to you and to all of the honorees!

Rod Mazandarani
Director of Science & Technology

carrierjohnson + CULTURE



Congratulations, KATE BRODERICK, Ph.D. (page 30)

Dr. Kate Broderick is Senior Vice President of Research & Development at TriLink BioTechnologies, part of Maravai LifeSciences. Kate is an expert in DNA technology and passionately leads TriLink's R&D initiatives. She brings **the miracles of science** to life each day in her work supporting mRNA-based vaccines, therapeutics, and cell and gene therapies.

Maravai celebrates Kate and everyone recognized as Leaders of Influence in the Life Science Industry.

Find Maravai in the top biotech list (page 24).

